Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells

@article{Sytkowski2007DoesEH,
  title={Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells},
  author={Arthur J. Sytkowski},
  journal={Science's STKE},
  year={2007},
  volume={2007},
  pages={pe38 - pe38}
}
  • A. Sytkowski
  • Published 17 July 2007
  • Biology, Medicine
  • Science's STKE
Erythropoietin (Epo) stimulates red blood cell production by docking with its cognate receptor on the erythroid progenitor cell and triggering an array of signaling pathways that inhibit apoptosis and promote cell proliferation and differentiation. In its pharmaceutical forms, epoetin and darbepoetin, Epo is widely used to treat various anemias, including those associated with cancer. The Epo receptor is also expressed by nonhematopoietic cells, including cancer cells, and Epo exhibits a… 

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

This article presents a short discussion of EPO, receptors involved in EPO signal transduction, and their action on non-hematopoietic cells, followed by a more detailed presentation of both pre-clinical and clinical data that demonstrate EPO’s action on cancer cells, as well as tumor angiogenesis and lymphangiogenesis.

The erythropoietin receptor in normal and cancer tissues.

The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells.

Erythropoietin Stimulates Tumor Growth via EphB4.

Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.

A careful gathering of Epo/EpoR biomolecular information enabled us to assemble an unexpected jigsaw puzzle which could explain most of the controversies of preclinical and clinical studies.

Erythropoietin Receptor Contributes to Melanoma Cell Survival in vivo

Recombinant Epo fails to stimulate melanoma growth in vivo, but the treatment increased vascular size in the xenografts and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo.

An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells

The data suggest that the coordinated regulation of a functional erythropoietin/erythropOietin receptor axis in prostate cancer cells may be integral to the growth and progression of prostate cancer.

References

SHOWING 1-10 OF 45 REFERENCES

Induction of Signalling in Non-Erythroid Cells by Pharmacological Levels of Erythropoietin

It is demonstrated that EPO, at pharmacological concentrations, can activate three major signalling cascades, viz. the Jak2/STAT5, Ras/ERK and PI3K/Akt pathways in non-small cell lung carcinoma (NSCLC) cell lines.

Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells

The hypothesis that Epo activates the Akt signaling pathway in human melanoma cells and thus promotes the survival of tumor cells is examined.

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

  • M. BrinesG. Grasso A. Cerami
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2004
The hypothesis that betacR in combination with the EpoR expressed by nonhematopoietic cells constitutes a tissue-protective receptor is hypothesized and supported, as predicted, neither Epo nor CEpo was active in cardiomyocyte or spinal cord injury models performed in the betac R knockout mouse.

Erythropoietin regulates tumour growth of human malignancies.

The findings suggest that Epo is indispensable for the growth and viability of malignant tumour and also that the deprivation of Epo signalling may be a promising therapy for human malignancy.

Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.

An endothelial cell protein of 45 kDa is identified as the principal receptor associated with this mitogenic effect of erythropoietin on human umbilical vein endothelial cells and bovine adrenal capillary endothelial Cells.

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

A role for autocrine or paracrine Epo signaling in the malignant progression and local invasiveness of head and neck cancer is supported and may also be activated by recombinant Epo therapy and could potentially produce detrimental effects in rhEpo-treated cancer patients.

Expression of erythropoietin receptor splice variants in human cancer.

Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis

The data suggest a critical role of the endogenous Epo/EpoR system in cervical cancer and their relationship with intratumoral pO2 levels as well as with survival in patients with cervical cancer.

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

Erythropoietin (Epo), the principal regulator of erythroid progenitor survival, growth, and differentiation, initiates its action by binding to its cognate cell surface receptor (EpoR). EpoR have